Senior Product Manager · Cancer Screening

Lunit unveils new ai-powered tumor microenvironment insights in Lung Cancer at WCLC 2026. 2026-09-08 21:00 205 Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ - Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the 2026 World Conference on Lung Cancer (WCLC 2026), to be held in Seoul, South Korea, from September 12 to 15. Across the three studies, Lunit researchers and collaborators leveraged AI-based analysis to investigate the tumor microenvironment (TME) in non-small cell lung cancer (NSCLC), exploring its relationship with genomic characteristics and treatment response. In the first study, researchers used Lunit SCOPE IO to analyze 494 hematoxylin and eosin (H&E)-stained whole-slide images from EGFR-mutant NSCLC cases, identifying distinct TME characteristics across mutation subtypes. Exon 19 deletion (Ex19del) tumors showed significantly lower intratumoral tumor-infiltrating lymphocyte (TIL) density, while L858R tumors showed relative enrichment of both TIL and macrophage infiltration, and exon 20 insertion (Ex20ins) tumors demonstrated higher endothelial cell density. The findings suggest that differences in treatment outcomes across EGFR mutation subtypes may involve not only kinase kinetics but also subtype-specific characteristics of the TME. In another study, conducted in collaboration with Paola Nisticò, M.D., of the Regina Elena National Cancer Institute in Rome, Italy researchers combined Lunit SCOPE IO with spatial transcriptomics and high-plex spatial proteomics to analyze 32 NSCLC patients treated with neoadjuvant chemo-immunotherapy. The study was conducted through the Lunit Research Program for SITC Members, which provides eligible Society for Immunotherapy of Cancer (SITC) members with research access to Lunit SCOPE IO for AI-powered tumor microenvironment analysis in cancer immunotherapy research. Tumors from patients who achieved pathological complete response (pCR) showed a highly inflamed and spatially organized microenvironment with prominent tertiary lymphoid structures (TLS), while non-pCR tumors were characterized by immune exclusion and activated fibroblast-rich stroma. The findings highlight distinct spatial and immunological features associated with pathological response and support further investigation of spatially resolved biomarkers. The third study evaluated an H&E-based AI model for predicting TP53 mutation status in lung adenocarcinoma. Validated in an independent cohort of 462 cases, the model achieved an area under the receiver operating characteristic curve (AUROC) of 0.759, with 82% sensitivity and 63% specificity. TME analysis further showed that TP53-mutant tumors were more frequently immune-inflamed, while TP53-wild-type tumors were characterized by immune exclusion and higher stromal fibroblast and endothelial cell densities. The findings highlight the potential of H&E-based AI as a screening tool to enrich for patients with TP53 mutations who may be eligible for emerging clinical trials targeting specific TP53 variants. "These studies demonstrate the expanding potential of AI-based analysis to generate deeper insights into lung cancer biology, from genomic characteristics and the tumor microenvironment to features associated with treatment response," said Brandon Suh, CEO of Lunit. "By broadening the range of insights that can be derived from routinely available pathology images, we aim to advance AI-powered biomarker discovery and patient stratification, ultimately contributing to more personalized treatment strategies for patients with cancer." Lunit's presentations at WCLC 2026 include: About Lunit Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Its clinically validated solutions span medical imaging, breast health, and biomarker analysis - empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum. Lunit offers a comprehensive suite spanning from risk prediction and early detection to precision oncology. Its FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development. Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact - for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

Leica Biosystems, Indica Labs partner with Lunit. May 29, 2026 - Leica Biosystems, Indica Labs, and Lunit are partnering to develop AI-powered image analysis algorithms. The collaboration will focus on PD-L1 and emerging immunohistochemistry biomarkers and brings together Leica Biosystems' PD-L1 IHC assay platform, Aperio GT 450 digital pathology scanner, Aperio Halo AP image management solution, and Lunit Scope biomarker scoring algorithm to deliver an AI-powered pathology workflow. The companies say the integrated workflow will support pharmaceutical partners conducting clinical research. "By combining Leica Biosystems' expertise in IHC staining and digital pathology, Indica Labs' image management platform, and Lunit's advanced AI analysis, the partnership aims to support consistent scoring approaches, enable robust biomarker analysis, and accelerate research," according to a joint press statement from the companies. The first product is an AI-powered Lunit Scope algorithm designed for Leica Biosystems' PD-L1 primary antibody (CAL10). The new algorithm, Lunit Scope PD-L1 CAL10 NSCLC, is for research use only and available now through Leica Biosystems' Aperio AI Store.

Industry leaders Leica Biosystems, Indica Labs and Lunit partner to develop ai-powered computational pathology Assays for PD-L1 and emerging biomarkers. Building on the market-defining computational pathology partnership between Leica Biosystems and Indica Labs, this new collaboration integrates Lunit's advanced AI capabilities into the best-in-class IHC staining and digital pathology ecosystem. VISTA, California, ALBUQUERQUE, New Mexico, and SEOUL, South Korea - May 26, 2026 - Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Indica Labs, a global leader in AI-powered digital pathology software, today announced a strategic collaboration with Lunit (KRX:328130.KQ), a leading provider of AI solutions for cancer diagnostics and therapeutics, to develop AI-powered image analysis algorithms. The partnership will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems' PD-L1 primary antibody (CAL10). The new algorithm, Lunit SCOPE PD-L1 CAL10 NSCLC[1], is now available through Leica Biosystems' Aperio AI Store. In driving this collaboration, Leica Biosystems will work together with Indica Labs and Lunit to support pharmaceutical partners in integrating AI-enabled digital pathology into routine clinical research. Today, biomarker scoring remains highly variable, as disease state assessments and treatment decisions often rely on manual evaluation of stained tissue under a microscope. This process can be time-consuming and prone to human variability. By combining Leica Biosystems' expertise in IHC staining and digital pathology, Indica Labs' image management platform, and Lunit's advanced AI analysis, the partnership aims to support consistent scoring approaches, enable robust biomarker analysis, and accelerate research workflows. The partnership brings together Leica Biosystems' PD-L1 IHC assay platform[1], Aperio GT 450 digital pathology scanner[1], Aperio HALO AP image management solution[2], and now Lunit SCOPE biomarker scoring algorithm[1] to deliver a seamless, AI-powered pathology workflow. "As a first step, we're integrating Lunit's algorithm directly into our image management software powered by Indica Labs, which enables a continuous workflow for users of the Aperio GT 450 scanner," said Karan Arora, SVP of Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems. "This launch aligns with our long-term vision to deliver scalable, seamlessly integrated research workflows to the market." This three-way integration reflects a shared commitment to open pathology and interoperability. Indica Labs CEO Steven Hashagen emphasized that "robust end-to-end solutions like these are a critical step toward realizing the promise of AI in digital pathology." Brandon Suh, CEO of Lunit, added, "We are encouraged by the strong interest from pharmaceutical partners and excited about the potential this collaboration holds. Together, we're applying AI to pathology image analysis at unprecedented scale, with a shared goal of delivering precision diagnostics that translate into tangible improvements in patient care." [1] For research use only. Not for use in diagnostic procedures. [2] Aperio HALO AP(R) is CE-IVDR marked for in vitro diagnostic use in Europe, the UK, and Switzerland. Aperio HALO AP(R) is for research use only in the US and is not FDA cleared for clinical diagnostic use. About Leica Biosystems Leica Biosystems is a cancer diagnostics company and a global leader in end-to-end anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company's mission of 'Advancing Cancer Diagnostics, Improving Lives' is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary. Learn more at www.leicabiosystems.com. About Indica Labs Indica Labs is the global leader in AI-powered digital pathology software and services. Its flagship HALO and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, Indica Labs Inc. help pharma companies, diagnostic labs, hospitals, research organizations, and Indica's own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery. About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 6,500 medical institutions in more than 65 countries, while Lunit SCOPE is used in research partnerships with global pharma giants focused on biomarker development and companion diagnostics. Lunit clinical studies have been featured in top-tier journals - including The Lancet Digital Health and Journal of Clinical Oncology - and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io. About Danaher Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through its connected ecosystem of industry-leading businesses, Indica Labs Inc. work side by side with customers to solve their most complex scientific and clinical challenges - helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, its advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, its approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.